iRhythm Holdings (IRTC)

The Zio system combines a small, wire-free patch worn on the chest with cloud-based software that analyzes electrocardiogram data. The patch can record continuously for up to 14 days, giving physicians a longer view of a patient’s heart rhythm than many traditional short-duration monitoring methods. This extended recording window can help identify intermittent arrhythmias that may not appear during a brief office visit or standard Holter test.

iRhythm’s service model includes the device, data processing, algorithm-assisted analysis, and a clinical report intended to support physician diagnosis. The company’s technology has received regulatory clearances in major markets, including the United States and Europe, and is used by healthcare providers evaluating conditions such as atrial fibrillation, bradycardia, tachycardia, and other rhythm abnormalities.

The company operates at the intersection of medical devices, software, and healthcare services. Its competitive position depends on clinical accuracy, ease of use for patients, integration into physician workflows, reimbursement coverage, and evidence supporting improved diagnostic yield. By combining wearable monitoring with proprietary analytics, iRhythm aims to make arrhythmia detection more efficient and accessible across routine care settings.